092040 — Amicogen Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for Amicogen, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	115,856	124,881	144,296	159,904	173,605
Cost of Revenue
Gross Profit	44,935	44,947	46,039	55,126	50,482
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	115,655	132,629	153,099	160,908	184,528
Operating Profit	201	-7,748	-8,804	-1,003	-10,923
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	40,814	9,663	-50,571	-23,230	-50,539
Provision for Income Taxes
Net Income After Taxes	32,291	4,741	-45,791	-20,690	-50,883
Minority Interest
Net Income Before Extraordinary Items
Net Income	31,604	3,733	-47,220	-23,289	-52,791
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	31,604	3,733	-47,220	-23,289	-52,791
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	822	134	-1,047	-531	-946
Dividends per Share